Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

This study is testing a combination of two immunotherapy drugs — iparomlimab and tuvonralimab — given before and after surgery in patients with resectable (surgically removable) non-small cell lung cancer (NSCLC). Using immunotherapy before surgery (neoadjuvant) aims to shrink the tumor and prime the immune system, while continuing it after surgery aims to eliminate any remaining cancer cells and reduce the chance of recurrence. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with stage II–IIIB (N2 only) NSCLC confirmed by biopsy - You have not received any prior treatment for this lung cancer - Your cancer is considered surgically removable - You have adequate general health and organ function (ECOG 0 or 1) **You may NOT be eligible if...** - Your cancer has spread beyond the chest or involves certain lymph node groups that make surgery impossible - You have an active autoimmune disease or are on long-term steroids - You have known driver mutations (like EGFR or ALK) that have approved targeted therapies - You have had prior immunotherapy or chest radiation - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.